

CT, LUNG CANCER STAGING

Date of examination

Patient's info – name, date of birth

Scanner brand and model

Scanning technique - number of detector rows

Slice thickness (mm) [numeric]

If contrast media is used – commercial name, volume (ml), flow rate (ml/s).

Findings:

• Lung lesion(s):

Location: [affected lobe, segment]

• Type of lesion [parenchymal, perifissural, subpleural, endobronchial]

Appearance: [solid, part-solid, ground glass]

O Size: [maximum diameter in one of the three planes in mm in lung window] In a part-solid tumor, the size of the solid component determines the T stage

O Infiltration of other structures: [aorta, pericardium, heart, bronchus, carina, diaphragm, pleura,

mediastinal fat, mediastinal structures, etc]

- O Atelectasis or obstructive pneumonia
- o Satellite nodules: [same/other lobe, same/other lung]
- Lymph nodes
- o Affected regional lymph nodes: [suspicious lymph nodes location should be reported according to the International Association of the Study of Lung Cancer (IASLC)]
- O Nonregional thoracic lymph node metastasis: [paracardial, internal mammary, intercostal, axillary,

peridiaphragmatic, etc]

Metastases

O Intrathoracic metastases: [malignant pleural/pericardial effusion, contralateral lesion, lymphangitic

carcinomatosis]

O Extrathoracic metastases:

February 2022





- Number: [singular, multiple]
- Location: [liver, bone, adrenal gland, lymph node, etc]
- Other findings [nononcologic]:
- O Structural lung changes [emphysema, fibrosis, etc]
- Heart/large vessels
- Nonmalignant findings in osseous structures
- O Abdominal organs as far as visible

Conclusion:

- T stage and invasion of surrounding structures:
- O TO [no primary tumor on imaging]
- o Tis [< 3 cm pure ground glass]</p>
- o Tmi [< 3 cm part-solid lesion with < 5 mm solid lesion]</p>
- o T1 [≤ 3 cm]
- T1a [≤ 1 cm]
- $T1b [> 1 to \le 2 cm]$
- $-T1c [> 2 to \le 3 cm]$
- O T2 [3 cm to \leq 5 cm or invasion of the visceral pleura, main bronchus, atelectasis, or obstructive pneumonitis extending to hilum]
- T2a [> 3 cm to ≤ 4 cm]
- $-T2b[> 4 cm to \leq 5 cm]$
- \circ T3 [> 5 to ≤ 7 cm or invasion of chest wall, pericardium, phrenic nerve, or separate tumor nodule(s) in same lobe]
- O T4 [> 7 cm or invasion of mediastinum (mediastinal fat), diaphragm, great vessels, spine, trachea, carina, esophagus, recurrent laryngeal nerve, or tumor nodule(s) in a different ipsilateral lobe]
- N stage
- O NO [no suspicious lymph nodes]
- N1 [ipsilateral peribronchial/hilar nodes]
- N2 [ipsilateral mediastinal/subcarinal nodes]
- N3 [contralateral mediastinal or hilar nodes; supraclavicular nodes]
 February 2022

AOSR Emerging Trends Committee Disease Specific Structured Reporting Template



- M stage
- O M0 [no evidence of metastasis]
- O M1a [intrathoracic metastasis (malignant pleural or pericardial effusion or pleural/pericardial nodules or separate tumor nodule(s) in a contralateral lobe)]
- O M1b [single extrathoracic metastasis]
- O M1c [multiple extrathoracic metastases]
- Further relevant findings